Section of Endocrinology, Department of Biomedical, Experimental and Clinical Sciences, University of Florence, Viale Pieraccini 6, 50134 Florence, Italy.
J Diabetes Res. 2013;2013:590456. doi: 10.1155/2013/590456. Epub 2013 Jun 18.
The introduction of incretin hormone-based therapies represents a novel therapeutic strategy, since these drugs not only improve glycemia with minimal risk of hypoglycemia, but also have other extraglycemic beneficial effects. These agents, which are effective in improving glucose control, could also have positive effects on the incidence of cardiovascular events. The aim of this review is to summarize the present literature about the role of dipeptidyl peptidase 4 (DPP4) in cardiovascular districts, not only strictly correlated to its effect on glucagon-like peptide-1 (GLP-1) circulating levels, but also to what is known about possible cardiovascular actions. Actually, DPP4 is known to be present in many cells and tissues and its effects go beyond purely metabolic aspects. Almost always the inhibition of DPP4 activity is associated with improved cardiovascular profile, but it has shown to possess antithrombotic properties and these different effects could be connected with a site and/or species specificity of DPP4. Certainly, DPP4 seems to exert many functions, both directly and indirectly, on cardiovascular districts, opening new possibilities of prevention and treatment of complications at this level, not only in patients affected by diabetes mellitus.
基于肠降血糖素类激素的治疗方法的引入代表了一种新的治疗策略，因为这些药物不仅能以低血糖风险最小化的方式改善血糖，而且还具有其他的血糖控制以外的有益作用。这些药物在改善血糖控制方面有效，也可能对心血管事件的发生率有积极影响。本综述的目的是总结目前关于二肽基肽酶 4（DPP4）在心血管区域的作用的文献，不仅与它对胰高血糖素样肽 1（GLP-1）循环水平的影响严格相关，还与已知的可能的心血管作用相关。实际上，DPP4 已知存在于许多细胞和组织中，其作用超出了纯粹的代谢方面。几乎总是，DPP4 活性的抑制与改善心血管状况相关，但它已显示出具有抗血栓特性，这些不同的作用可能与 DPP4 的位点和/或物种特异性有关。当然，DPP4 似乎对心血管区域直接和间接地发挥许多功能，为该水平的并发症的预防和治疗开辟了新的可能性，不仅在患有糖尿病的患者中如此。
